Immune to Cancer: The CRI Blog
-
FDA Approves Immunotherapy to Help Prevent Relapse of Melanoma
The immunotherapy drug ipilimumab (Yervoy®) can now be used to help prevent relapse after surgery.
-
FDA Approves First in a New Class of Immunotherapies
Amgen’s oncolytic virus immunotherapy, T-VEC, gets the green light from the FDA.
-
What Is an Oncogene? Immunologists Rethink a Fundamental Cancer Concept
Immunology is reshaping how oncologists think about cancer, and even basic principles—like oncogenes—are getting a significant makeover.
-
FDA Approves Expanded Use of Nivolumab for Lung Cancer
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung…
-
FDA Approves PD-1 Immunotherapy for Most Common Type of Lung Cancer
Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.
-
In a First, FDA Approves Immunotherapy Combination for Advanced Melanoma
The approval of a combination of two immunotherapy drugs for melanoma represents a treatment milestone.
-
New Study: Vaccine Holds Promise in Treating Cervical Pre-Cancer
The vaccine could provide a new treatment option for patients with high-risk cervical pre-cancer.
-
Clinton and Cuomo Applaud the Work of CRI Scientists at Annual Awards Dinner
The two politicians were united in their support for the work done by cancer immunotherapy researchers.
-
Love Is On
Share the love with CRI in the Revlon LOVE IS ON Million Dollar Challenge.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.